TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06733935: A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Sponsor: Nkarta, Inc. · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 240 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$351,900

Rescue Site Savings

+$234,600

Unlock Full NCT06733935 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06733935 Rescue Dossier →